# Betta Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/betta-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.bettapharma.com
- Latest round: Series B (Jun 1, 2013)
- Investors on record: 2

## About

Founded in 2003 and based in Yuhang, China, Betta Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of pharmaceuticals for the treatment of cancer. The company has new drug development centers in Beijing and Hangzhou. In November 2016, this company was listed on the Shenzhen Stock Exchange. The company launched a small-molecule targeted anticancer drug in June 2011, icotinib hydrochloride. In June 2023, it launched Vorolanib Tablets (trade name: Vermina®).

The company’s main business is the research, development, production and marketing of innovative drugs. The company’s self-developed products include Icotinib Hydrochloride (Conmana®), Ensartinib Hydrochloride Capsules (Bemaner®), Bevacizumab Injection (Beianting®), Befotertinib Mesylate Capsules (Saimeina®), and Vorolanib Tablets (Fumeina®). Its products are used in the fields of malignant tumors, ophthalmology, autoimmune diseases and diabetes.

The company generates revenue by providing innovative drug products and related services.

## Funding rounds

- Series B, Jun 1, 2013 — Hong Shan
- Series A, Jun 1, 2010 — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Hong Shan — Series B